

ENOS WELCOMES NEW UK CENTRES

The ENOS acronym stands for "Efficacy of Nitric Oxide in Stroke". This study is an international, multicentre, trial investigating the safety and efficacy of treatment with transdermal glyceryl trinitrate, a nitric oxide donor, and of continuing or stopping prior antihypertensive therapy, in patients with acute ischaemic or haemorrhagic stroke.

UK CENTRE VISITS

In the last couple of months our trial manager has made several site visits throughout the UK, covering approximately 600 miles in total. This began with a trip to Bishop Auckland for a start-up visit at the General Hospital - Dr Ali Mehrzad, the lead investigator, is pictured below:



In addition to this, following notification of local ethics approval, start-up visits were made at the Delancey Hospital, Cheltenham (Lead investigator: Dr A Deering) and the Royal Hallamshire in Sheffield (Lead investigator: Dr G Venables). We'd like to thank all these centres for their efforts in obtaining early approval and their help during these visits.

CANADA APPROVES USE OF GTN FOR ENOS

We are pleased to announce the Canadian national drug regulatory body, Health Canada, has recently approved the use of glyceryl trinitrate for use in the ENOS trial. We are therefore especially keen to hear from any Canadian centres that are considering joining the trial.

CONGRATULATIONS

Congratulations to our new UK centres in Bishop Auckland, and Sheffield for recruiting their first patients into the trial. As always, we welcome other interested sites to fax, email or post the form which is attached with this newsletter to the ENOS trial office (addresses below). Alternatively, you can access this form at the ENOS trial website.

ENOS RECRUITMENT

NOTTINGHAM CITY HOSPITAL 29 PATIENTS
SINGAPORE GENERAL HOSPITAL 15 PATIENTS
GLAN CLWYD GENERAL HOSPITAL 0 PATIENTS
ROYAL HALLAMSHIRE, SHEFFIELD 1 PATIENT

NOTTINGHAM, QUEEN'S MEDICAL CENTRE 0 PATIENTS
BISHOP AUCKLAND GENERAL HOSPITAL 1 PATIENT
DELANCEY HOSPITAL, CHELTENHAM 0 PATIENTS